Santhera Pharmaceuticals Holding AG (SPHDF)
| Previous close | 13.35 |
| Open | 13.35 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 13.35 - 13.35 |
| 52-week range | 0.68 - 13.35 |
| Volume | |
| Avg. volume | 159 |
| Market cap | 155.837M |
| Beta (5Y monthly) | 0.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -9.87 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireSanthera Appoints Executive Committee Members as it Transitions into Commercial Stage
Pratteln, Switzerland, December 7, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the promotion of Geert Jan van Daal, MD, PhD, to Chief Commercial Officer (CCO) and of Marc Schrader to Chief Technology Officer (CTO). Both will join the six-member Executive Committee effective January 1, 2024. “Santhera is transitioning to the commercial phase and will make AGAMREE® (vamorolone) available to patients in Europe starting in Germany in early 2024, subject to approval by the European Commissi
- GlobeNewswire
Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy
Ad hoc announcement pursuant to Art. 53 LR Food and Drug Administration (FDA) approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in children and adults aged 2 years and olderU.S. license holder Catalyst Pharmaceuticals plans for commercial launch in Q1-2024FDA approval triggers USD 36 million payment obligation from Catalyst to Santhera, of which USD 26 million will be used to cover Santhera’s third-party milestone obligationsFollowing the recent positive CHMP
- GlobeNewswire
Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy
Ad hoc announcement pursuant to Art. 53 LR Committee for Medicinal Products for Human Use (CHMP) issues positive opinion for AGAMREE® (vamorolone) for the treatment Duchenne muscular dystrophy (DMD) in children and adults aged 4 years and olderEuropean Commission (EC) decision on marketing authorization is expected in late 2023AGAMREE could become the first drug fully approved by the European Medicines Agency (EMA) for the treatment of patients with DMD Anticipation of vamorolone approval in the
